

November 2011

Press Release

Tsutomu Sugaya  
Executive Officer  
Head of Administrative Affairs and Corporate Planning  
Nobelpharma Co., Ltd.

Announcing a Press Conference by the President of Nobelpharma Co., Ltd.

Nobelpharma has consistently focused on development of drugs for unmet medical needs since the Company was established in June 2003. The Company received approval of Manufacturing and Marketing Authorization for its first three products in 2008, taking the first major step in its business. In July this year the company received approval of Manufacturing and Marketing Authorization for its fourth product, NPC-06 Fostoin for injection (anticonvulsant drug; Fosphenytoin), and is currently preparing to launch it. In December the Company will end its 9<sup>th</sup> fiscal year, and anticipates clearing its books of all accumulated losses so far, including research and development investments.

We will hold a press conference as described below by President Jin Shiomura of Nobelpharma Co., Ltd., covering the subject of “Summary of Business Activities and Outlook for the 9<sup>th</sup> Fiscal year (January through December 2011), as well as Future Prospects.” We hope that you will find time from your busy schedule to attend this press conference.

Date and time: Doors open at 13:30, November 11, 2011 (Friday)

Location: The Foreign Correspondents' Club of Japan  
Yurakucho Denki North Building 20F  
Yurakucho 1-7-1, Chiyoda-ku, Tokyo, 100-0006  
03-3211-3161

<http://www.e-fccj.com/aboutus/map>

<p>Please direct inquiries to: Tsutomu Sugaya Executive Officer, Head of Administrative Affairs and Corporate Planning Nobelpharma Co., Ltd. 12-10 Nihonbashi-kobunacho, Chuo-ku, Tokyo, 103-0024 03-5651-1160</p>
--